| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 05/31/2007 | US20070123487 Methods and Compositions for Treating Prostate Cancer Using DNA Vaccines |
| 05/31/2007 | US20070123479 single chain antibody construct comprising binding domains specific for human CD3 and human CD19; anticarcinogenic biodrug for treating non-Hodgkin lymphoma |
| 05/31/2007 | US20070123466 Method of treating recurrent miscarriages |
| 05/31/2007 | US20070123459 IL-17 like molecules and uses thereof |
| 05/31/2007 | US20070122853 Methods and compositions for detecting larval Taenia solium with a cloned diagnostic antigen |
| 05/31/2007 | US20070122813 Use of cripto-1 as a biomarker for neurodegenerative disease and method of inhibiting progression thereof |
| 05/31/2007 | US20070122802 Methods of diagnosing and treating diabetes and insulin resistance |
| 05/31/2007 | US20070122434 Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus |
| 05/31/2007 | US20070122433 Less painful immunogenic composition of a hydrophobic protein; solubilizing hydrophobic protein with a zwitterionic detergent to make a composition that is then altered; meningitis or gonorrhea |
| 05/31/2007 | US20070122432 Compositions and methods of treating retroviral infections |
| 05/31/2007 | US20070122431 Reverse genetic system for Rift Valley fever virus and uses thereof |
| 05/31/2007 | US20070122430 Influenza vaccine compositions and methods of use thereof |
| 05/31/2007 | US20070122429 Designed antigens to elicit neutralizing antibodies against sterically restricted antigen and method of using same |
| 05/31/2007 | US20070122428 Genetically modified cholera toxin (CT-CRM) comprising reduced toxicity and enhanced immunological response for use in preparation of vaccines against parasitic infection |
| 05/31/2007 | US20070122427 Delivery of trefoil peptides |
| 05/31/2007 | US20070122425 fusion protein comprising a periplasmic targeting signal and at least one antimicrobial peptide; use as microbiocides; from Gram negative bacteria transformed host cell; nontoxic and proteolytic non-degradation, simple, inexpensive recovery of the peptide; industrial scale production; on medical devices |
| 05/31/2007 | US20070122424 Peptide-based vaccine for influenza |
| 05/31/2007 | US20070122423 Derp1 and proderp1 allergen derivatives |
| 05/31/2007 | US20070122422 Sodium-independent small neutral amino acid transporter transporting L- and D- amino acids |
| 05/31/2007 | US20070122421 Flagellin fusion for use in generating vaccines for prevention and treatment of tumors, allergens and nervous system disorders |
| 05/31/2007 | US20070122420 Protein antigens useful for cancer therapy and vaccination |
| 05/31/2007 | US20070122419 Methods and compositions for treating atherosclerosis |
| 05/31/2007 | US20070122418 Compositions and methods for the pulmonary delivery of aerosolized medicaments |
| 05/31/2007 | US20070122417 Immunotherapy method |
| 05/31/2007 | US20070122416 Cross-reactive displacing antibodies from collagen-binding proteins and method of identification and use |
| 05/31/2007 | US20070122415 Compound and method for suppressing retroviral replication |
| 05/31/2007 | US20070122414 Surface marker-directed cancer therapeutics |
| 05/31/2007 | US20070122413 Il-21 antagonists |
| 05/31/2007 | US20070122412 Eg-vegf nucleic acids and polypeptides and methods of use |
| 05/31/2007 | US20070122411 Solid forms of anti-egfr antibodies |
| 05/31/2007 | US20070122410 Use of an active substance binding to CD28 for producing a pharmaceutical composition for the treatment of B-CLL |
| 05/31/2007 | US20070122409 Compounds, Compositions and Methods for the Endocytic Presentation of Immunosuppressive Factors |
| 05/31/2007 | US20070122408 Fc Labeling for Immunostaining and Immunotargeting |
| 05/31/2007 | US20070122407 ISOLATED NUCLEIC ACIDS, VECTORS AND HOST CELLS ENCODING ErbB3 ANTIBODIES |
| 05/31/2007 | US20070122406 Humanized Epithelial cell adhesion molecule (Ep-CAM) antibodies; cytotoxic chemotherapeutics; antitumor agents |
| 05/31/2007 | US20070122405 Human G-protein chemokine receptor (CCR5) HDGNR10 |
| 05/31/2007 | US20070122404 Humanized immunoglobulin reactive with alpha4beta7 integrin |
| 05/31/2007 | US20070122403 Molecules with extended half-lives, compositions and uses thereof |
| 05/31/2007 | US20070122402 Immunoglobulin preparations having increased stability |
| 05/31/2007 | US20070122383 Interleukin-10 compositions for the treatment of adenocarcinomas |
| 05/31/2007 | US20070122382 Methods of treating cancer using il-21 and monoclonal antibody therapy |
| 05/31/2007 | US20070122379 Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms |
| 05/31/2007 | US20070122378 Methods and compositions for the treatment of persistent infections |
| 05/31/2007 | US20070122377 Compositions and methods of treatment |
| 05/31/2007 | US20070122323 Vapor phase growth apparatus and method of fabricating epitaxial wafer |
| 05/31/2007 | CA2631015A1 Human monoclonal antibody human cd134 (ox40) and methods of making and using same |
| 05/31/2007 | CA2630964A1 Antibody treatment of alzheimer's and related diseases |
| 05/31/2007 | CA2630920A1 Inhibition of cell proliferation |
| 05/31/2007 | CA2630840A1 Allergy treatment by epicutaneous allergen administration |
| 05/31/2007 | CA2630770A1 Recombinant polyvalent vaccine |
| 05/31/2007 | CA2630629A1 Methods and proteins for the prophylactic and/or therapeutic treatment of the four serotypes of dengue virus and other flaviviruses |
| 05/31/2007 | CA2630404A1 Method for de-esterification of the lipopolysaccharide layer of neisseria meningitidis and mannheimia haemolytica |
| 05/31/2007 | CA2630283A1 Recombinant plasmodium falciparum merozoite surface proteins 4 and 5 and their use |
| 05/31/2007 | CA2630115A1 Immunoglobulin fusion protein formulations |
| 05/31/2007 | CA2629193A1 Coatable compositions, coatings derived therefrom and microarrays having such coatings |
| 05/31/2007 | CA2629147A1 Humanized immunoglobulin reactive with .alpha.4.beta.7 integrin |
| 05/31/2007 | CA2628126A1 Monoclonal antibodies against claudin-18 for treatment of cancer |
| 05/30/2007 | EP1790730A2 Streptococcus pneumoniae proteins and nucleic acid molecules |
| 05/30/2007 | EP1790729A2 Streptococcus pneumoniae proteins and nucleic acid molecules |
| 05/30/2007 | EP1790728A2 Imaging, diagnosis and treatment of disease |
| 05/30/2007 | EP1790727A2 Proteins and nucleic acids encoding same |
| 05/30/2007 | EP1790725A2 Proteins named after FCTRX and nucleic acids encoding same |
| 05/30/2007 | EP1790716A1 Uses of the FcRn receptor |
| 05/30/2007 | EP1790664A1 Monoclonal antibodies against claudin-18 for treatment of cancer |
| 05/30/2007 | EP1790663A1 Monoclonal antibody(ad5-10) against tumor necrosis factor-related apoptosis-inducing ligand receptor dr5, the producing method and uses thereof |
| 05/30/2007 | EP1790662A1 Nucleic acid and corresponding protein entitled 121P2A3 useful in treatment and detection of cancer |
| 05/30/2007 | EP1790659A2 Polypeptides of pseudomonas aeruginosa |
| 05/30/2007 | EP1790332A1 Vaccine for oral administration |
| 05/30/2007 | EP1789800A2 Ileitis diagnostic assay |
| 05/30/2007 | EP1789593A2 Soluble forms of hendra and nipah virus g glycoprotein |
| 05/30/2007 | EP1789590A2 Arf-bp1 as mediator of p53-dependent and independent tumor suppression and uses thereof |
| 05/30/2007 | EP1789566A1 Nucleic acid sequences encoding proteins capable of associating into a virus-like particle |
| 05/30/2007 | EP1789559A2 Methods for constructing antibiotic resistance free vaccines |
| 05/30/2007 | EP1789554A1 Recombinant vaccines against caligid copepods (sea lice) and antigen sequences thereof |
| 05/30/2007 | EP1789532A1 Shigella mutants in the functions pertaining to the processes of maturing and recycling peptidoglycans and their uses as immunogens |
| 05/30/2007 | EP1789451A2 Tie complex binding proteins |
| 05/30/2007 | EP1789450A1 Use of ilt6 for immunomodulation |
| 05/30/2007 | EP1789449A1 Anti-glycated cd59 antibodies and uses thereof |
| 05/30/2007 | EP1789448A2 PROTECTIVE ANTI-GLUCAN ANTIBODIES WITH PREFERENCE FOR ß-1,3-GLUCANS |
| 05/30/2007 | EP1789438A2 Recombinant mva viruses expressing glade a/g, clade b, and clade c modified hiv, gag and pol genes |
| 05/30/2007 | EP1789093A2 Antibody vaccine conjugates and uses therefor |
| 05/30/2007 | EP1789087A2 Engineered antibody fragment that irreversibly binds an antigen |
| 05/30/2007 | EP1789086A2 Extended treatment of multiple sclerosis |
| 05/30/2007 | EP1789085A2 Change of the load state of mhc molecules |
| 05/30/2007 | EP1789084A1 Decreasing potential iatrogenic risks associated with influenza vaccines |
| 05/30/2007 | EP1789083A1 Prevention of allergy in children |
| 05/30/2007 | EP1789082A1 Cytokine-expressing cellular vaccines for treatment of prostate cancer |
| 05/30/2007 | EP1789081A2 Treatment of atherosclerosis |
| 05/30/2007 | EP1789071A2 Pik4ca as modifier of the rac pathway and methods of use |
| 05/30/2007 | EP1789059A2 Glycosylceramide adjuvant for saccharide antigens |
| 05/30/2007 | EP1373487B1 Regulation of human protein kinase-like protein |
| 05/30/2007 | EP1311663B1 Claudin polypeptides |
| 05/30/2007 | EP1221973B1 CD40 antagonist for treating psoriasis |
| 05/30/2007 | EP1206274B1 Use of interleukin-18 inhibitors to inhibit tumor metastasis |
| 05/30/2007 | EP0975754B1 Osteoprotegerin binding proteins and receptors |
| 05/30/2007 | EP0692974B2 Multicomponent clostridial vaccines using saponin adjuvants |
| 05/30/2007 | CN1973053A Novel anti-IL 13 antibodies and uses thereof |
| 05/30/2007 | CN1973040A EphA4 as therapeutic target of PRC and PDACa |
| 05/30/2007 | CN1973030A Dendritic cell obtained by antigen pulsing |
| 05/30/2007 | CN1972958A Method of using adenoviral vectors to induce an immune response |